Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL EBITDA Margin
EBITDA as a percentage of revenue.
Autolus Therapeutics plcNASDAQ: AUTL
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -217.2%
EBITDA Margin was -217.2% in Q1 FY2026, up 400.9 pp from a year earlier. On a trailing-twelve-month basis it was -249.3%, up 2401.7 pp year over year. Over 3 fiscal years it widened by 1803.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -96.6% for the fiscal year ending Dec 2026, up from -331.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -217.2%+54.8 pp QoQ
- Last fiscal yearDec 2025
- -331.2%+1971.9 pp YoY
- LTMMar 2026
- -249.3%+2401.7 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -331.2%
- Year-over-year change
- +1971.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -331.2% | +1971.9pp |
| FY2024 | 2024-12-31 | -2303.1% | +6929.5pp |
| FY2023 | 2023-12-31 | -9232.6% | -7097.7pp |
| FY2022 | 2022-12-31 | -2135.0% | +6655.7pp |
| FY2021 | 2021-12-31 | -8790.6% | — |
EBITDA Margin vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 EBITDA Margin of -249.3% is the 6th highest of the 9 companies compared; the peer median is -82.4%.
- Its year-over-year change of +2401.7 pp is the highest of 9, against a peer median of -13.8 pp.
- Over three fiscal years its change of +1803.8 pp compares with a peer median of +229.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 7.3% | +27.5 pp | +333.4 pp | |
| FY2025 | 3.2% | +1695.0 pp | +2334.4 pp | |
| LTM Mar 2026 | -23.7% | -20.8 pp | +381.6 pp | |
| LTM Mar 2026 | -75.1% | -6.9 pp | +343.8 pp | |
| LTM Mar 2026 | -89.7% | -57.3 pp | +126.4 pp | |
| LTM Mar 2026 | -249.3% | +2401.7 pp | +1803.8 pp | |
| LTM Mar 2026 | -999.5% | +475.3 pp | -608.7 pp | |
| LTM Mar 2026 | -1859.1% | -709.8 pp | -1633.0 pp | |
| LTM Mar 2026 | -770932.3% | -482924.6 pp | -730107.8 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding AUTL) | -82.4% | -13.8 pp | +229.9 pp | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.51M | 6.19M | 1.7M | 10.12M | 75.56M |
| Cost of Revenue | 0 | 0 | 0 | 141.02M | 96.59M |
| Gross Profit | 1.51M | 6.19M | 1.7M | (130.9M) | (21.03M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| Research & Development | 110.84M | 117.35M | 130.48M | 158.14M | 128.59M |
| Selling, General & Admin | 31.87M | 31.9M | 46.75M | 0 | 131.82M |
| Operating Expenses | 141.88M | 149.09M | 181.4M | 110.53M | 260.41M |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.84M |
| EBITDA | (132.48M) | (132.24M) | (156.77M) | (233.07M) | (250.26M) |
| EBITDA Margin | -8790.6% | -2135.0% | -9232.6% | -2303.1% | -331.2% |
| Operating Income | (140.37M) | (142.89M) | (179.7M) | (241.43M) | (281.44M) |
| Operating Margin | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% |
| Interest Income | 262K | 1.71M | 13.51M | 32.36M | 19.02M |
| Interest Expense | 1.11M | 8.91M | 45.07M | 9.29M | 36.76M |
| Other Income / Expenses | (1.66M) | (5.67M) | (28.7M) | 22.29M | (15.41M) |
| Income Before Tax | (142.04M) | (148.57M) | (208.4M) | (219.13M) | (296.85M) |
| Pre-Tax Margin | -9425.2% | -2398.6% | -12273.4% | -2165.4% | -392.8% |
| Income Tax Expense | 58K | 272K | (19K) | 1.53M | (8.65M) |
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (288.2M) |
| Net Margin | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% |
| EPS (Basic) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| EPS (Diluted) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| Weighted Avg Shares | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Weighted Avg Shares (Diluted) | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.